#1 Clinical Trials Search in Europe

Medi0618

MEDI0618 is an innovative drug currently being studied in clinical trials for its potential in treating migraine and chronic pain. This article explores the ongoing research, including safety assessments, efficacy evaluations, and pharmacokinetic studies of MEDI0618 in both healthy volunteers and patients with episodic migraine. The trials aim to determine the drug’s effectiveness, optimal dosing, and potential side effects, offering hope for those seeking new treatment options for migraine and chronic pain management.

Table of Contents

What is MEDI0618?

MEDI0618 is a new medication currently being studied for its potential in treating chronic pain and migraine. It is classified as a novel human immunoglobulin antibody, which means it’s a type of protein designed to interact with specific targets in the body[1]. More specifically, MEDI0618 is known as a Protease-Activated Receptor 2 (PAR2) Antagonist[3]. This scientific name tells us that the drug works by blocking a specific receptor in the body that is involved in pain signaling.

How Does MEDI0618 Work?

While the exact mechanism of action is still being studied, we know that MEDI0618 targets the Protease-Activated Receptor 2 (PAR2). This receptor is involved in various processes in the body, including inflammation and pain signaling. By blocking this receptor, MEDI0618 may help reduce pain and inflammation in conditions like chronic pain and migraine[3].

Conditions Treated by MEDI0618

Based on the ongoing clinical trials, MEDI0618 is being investigated for the treatment of two main conditions:

  • Chronic Pain: This is a persistent pain that lasts for weeks, months, or even years. It can significantly impact a person’s quality of life and daily activities[1][3].
  • Episodic Migraine: This refers to migraine headaches that occur occasionally, typically less than 15 days per month. Migraines are severe headaches often accompanied by other symptoms like nausea and sensitivity to light and sound[2].

Clinical Trials and Research

MEDI0618 is currently undergoing several clinical trials to evaluate its safety, effectiveness, and how it’s processed by the body (pharmacokinetics). These trials include:

  1. Safety and Pharmacokinetics Study: This study is testing single doses of MEDI0618 in healthy volunteers to understand how safe it is and how it moves through the body[1].
  2. Migraine Prevention Study: This larger study is looking at how effective MEDI0618 is in preventing migraine headaches in people with episodic migraine. It’s comparing different doses of MEDI0618 to a placebo (a substance with no active medication)[2].
  3. Multiple Dose Safety Study: This study is examining the safety and pharmacokinetics of multiple doses of MEDI0618 in healthy volunteers[3].

How is MEDI0618 Administered?

MEDI0618 is being tested in two main forms of administration:

  • Intravenous (IV) Infusion: This means the medication is given directly into a vein through a needle or catheter[1][3].
  • Subcutaneous (SC) Injection: This involves injecting the medication just under the skin[1][2][3].

The dosing schedule varies depending on the study, but some trials are testing doses given once every two weeks[3].

Safety and Side Effects

As MEDI0618 is still in the research phase, its full safety profile is not yet known. The ongoing clinical trials are carefully monitoring for any side effects or adverse reactions. Some of the key safety measures being evaluated include:

  • Incidence of adverse events (any unfavorable medical occurrences during the study)[1][3]
  • Changes in vital signs (such as heart rate and blood pressure)[1][3]
  • Changes in laboratory test results (including blood and urine tests)[1][3]
  • Development of anti-drug antibodies (the body’s immune response to the medication)[3]

It’s important to note that as a new medication, MEDI0618 is not yet approved for general use. Its safety and effectiveness are still being evaluated in clinical trials. Patients interested in this treatment should discuss it with their healthcare provider and consider participating in clinical trials if appropriate.

Aspect Details
Drug Name MEDI0618
Drug Type Human immunoglobulin antibody (Protease Activated Receptor 2 Antagonist)
Conditions Studied Episodic Migraine, Chronic Pain
Administration Methods Intravenous (IV) infusion, Subcutaneous (SC) injection
Trial Phases Phase 2 (Migraine), Early-phase (Healthy Volunteers)
Primary Outcomes Safety, Tolerability, Efficacy in reducing Migraine Headache Days
Secondary Outcomes Pharmacokinetics, Disability reduction (MIDAS score), Migraine severity reduction
Study Designs Randomized, Double-blind, Placebo-controlled

FAQ

  • What is MEDI0618? MEDI0618 is a novel human immunoglobulin antibody being studied as a potential treatment for migraine and chronic pain. It is designed to target specific receptors involved in pain signaling.
  • What conditions is MEDI0618 being tested for? MEDI0618 is primarily being tested for episodic migraine and chronic pain. Clinical trials are evaluating its safety, efficacy, and pharmacokinetics in these conditions.
  • How is MEDI0618 administered in clinical trials? In the clinical trials, MEDI0618 is administered either through intravenous (IV) infusion or subcutaneous (SC) injection, depending on the specific study protocol.
  • What are the main goals of the MEDI0618 clinical trials? The main goals of the clinical trials are to assess the safety and tolerability of MEDI0618, evaluate its efficacy in reducing migraine headache days, and understand its pharmacokinetic profile (how the drug moves through the body).
  • Are there any known side effects of MEDI0618? As MEDI0618 is still in clinical trials, the full range of potential side effects is not yet known. The trials are designed to monitor and record any adverse events to establish the safety profile of the drug.

Ongoing Clinical Trials on Medi0618

  • Study on the Safety and Effectiveness of MEDI0618 for Reducing Migraine Days in Adults with Episodic Migraine

    Recruiting

    2 1
    Investigated drugs:
    Czechia Denmark Germany Hungary Italy The Netherlands +2

Glossary

  • Episodic Migraine: A condition characterized by recurring headaches that typically last 4-72 hours, occurring less than 15 days per month.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Placebo: An inactive substance that looks like the drug being tested but contains no active ingredient, used to compare the effects of the real drug.
  • Double-blind Study: A research design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Subcutaneous (SC) Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Intravenous (IV) Infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Migraine Headache Days (MHDs): The number of days in a month when a person experiences a migraine headache, used to measure the frequency of migraines.
  • Anti-drug Antibodies (ADA): Antibodies produced by the body's immune system in response to a therapeutic drug, which can potentially affect the drug's efficacy or safety.
  • Protease Activated Receptor 2 (PAR2): A protein involved in pain signaling pathways, which is the target of MEDI0618 in its mechanism of action.
  • MIDAS Score: Migraine Disability Assessment Score, a tool used to measure the impact of migraines on a person's daily activities and quality of life.

References